GAMMA Investing’s C4 Therapeutics CCCC Stock Holding History

GAMMA Investing’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-217	Closed	-$1.24K	–	3787
2024 Q3	$1.24K	Buy	+217	New	+$1.31K	﹤0.01%	3201

Other funds holding CCCC

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GAMMA Investing's CCCC Position: Q4 2024 in Review

GAMMA Investing sold out of C4 Therapeutics (CCCC) in Q4 2024, closing a stake of 217 shares — an estimated $1.24K sold.

GAMMA Investing first reported a position in CCCC in Q3 2024 and held it in 1 quarter. The position peaked at $1.24K in Q3 2024. 113 funds tracked by Wall St. Rank hold CCCC as of Q4 2024.

GAMMA Investing reported no remaining C4 Therapeutics position as of Q4 2024 after selling out during the quarter.
GAMMA Investing sold 217 C4 Therapeutics shares in Q4 2024, an estimated $1.24K.
GAMMA Investing first reported a position in C4 Therapeutics in Q3 2024 and held it in 1 quarter.
GAMMA Investing's C4 Therapeutics position peaked at $1.24K in Q3 2024.
113 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2024.

Based on GAMMA Investing's 13F filing for Q4 2024, filed 3 Jan 2025.